French National Agency for Medicines and Health Products Safety

Report No: ***15MPP048NCS***

STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer [1]

Part 1

Issued following an inspection in accordance with :
Art. 111(7) of Directive 2001/83/EC as amended

The competent authority of France confirms the following:
The manufacturer: ***MINSHENG GROUP SHAOXING PHARMACEUTICAL CO. LTD***
Site address: ***315 Tanggong Road, Paojiang Industrial Zone, Shaoxing, ZHEJIANG, 312071, China***

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2015-05-22*** , it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

- The principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC .

[1] *The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and 80(7) of Directive 2001/82/EC, as amended, shall also be required for imports coming from third countries into a Member State.*

Part 2

1 NON-COMPLIANT MANUFACTURING OPERATIONS	
Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary;	
1.2	**Non-sterile products**
	1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.17 Other: Active Substance(en)

Manufacture of active substance. Names of substances subject to non-compliant :
PRAZIQUANTEL(en)

Part 3

1. Nature of non-compliance:

Overall, 18 deficiencies were observed during the inspection, including 2 Critical and 4 Major deficiencies: [Critical 1] Falsification of source of API (Thiamphenicol): Repackaging, relabeling and selling of purchased API from a non-GMP company (Zhejiang Runkang Pharmaceutical Co.Ltd.) as if manufactured in-house; [Critical 2] Praziquantel manufactured according to CP process/grade was released as USP process/grade without a full traceability of the testing activities ; [Major 1] The maintenance and the cleaning operations of the manufacturing line used for the production of Praziquantel (API) were found deficient; [Major 2] The pipes design of some equipment used for the manufacturing of Praziquantel, the handling of change related to these equipment and the instruction used for the transfer of the intermediate solution using nitrogen were found deficient ; [Major 3] The hoses used for unloading of solvent were not identified, had no cleaning status and were stored on a dirty floor of an area not mentioned in the general layout of the site; [Major 4] There was no procedure in place for audit trail and there was no effective audit trail in place to determine any change or deletion of the chromatographic raw data. The audit trial function including the administrator profiles was enabled for all the QC staff.

Action taken/proposed by the NCA

Recall of batches already released
Consideration of a recall of product should be given due to the critical findings observed. Using QRM principles, National supply situation and clinical requirements should be taken into account when making this decision.

Prohibition of supply
The site has been issued a statement of non compliance and should not be named on any marketing authorisations whilst this statement remains in place.

Others
Withdrawal, of current valid GMP certificate(s): Using QRM principles, consideration of withdrawal of current valid EU GMP certificate issued by Austrian Federal Office for Safety in Health Care (n° INS-482393-0001-008);

Additional comments
The inspection was performed in the framework of WHO prequalification of medicines programme for the manufacture of Praziquantel API.

2015-12-28

Name and signature of the authorised person of the Competent Authority of France

---

Confidential
French National Agency for Medicines and Health Products Safety
Tel: ***Confidential***
Fax: ***Confidential***